Sort   by:  
 Page size 
ProteomicsLC-MSMS of primary AML class I immunopeptidome (mTECs k-mer depletion approach)
The development of therapeutic anticancer vaccines calls for the identification of tumor-specific antigens (TSAs). Though a combination of four cutting-edge proteogenomic approaches, we performed a deep exploration of the MHC-I presented peptides (MAPs) of 19 acute myeloid leukemia (AML) patients an...
ORGANISM(S): Homo sapiens (Human) 
2021-03-19 | PXD018540 | Pride
Aml Lc-msms Immunopeptidome Mhc class i 
ProteomicsLC-MSMS of primary AML class I immunopeptidome (ERE-derived MAPs identification approach)
The development of therapeutic anticancer vaccines calls for the identification of tumor-specific antigens (TSAs). Though a combination of four cutting-edge proteogenomic approaches, we performed a deep exploration of the MHC-I presented peptides (MAPs) of 19 acute myeloid leukemia (AML) patients an...
ORGANISM(S): Homo sapiens (Human) 
2021-03-19 | PXD018542 | Pride
Aml Lc-msms Immunopeptidome Mhc class i 
ProteomicsLC-MSMS of primary AML class I immunopeptidome (mTECs+MPCs k-mer depletion approach)
The development of therapeutic anticancer vaccines calls for the identification of tumor-specific antigens (TSAs). Though a combination of four cutting-edge proteogenomic approaches, we performed a deep exploration of the MHC-I presented peptides (MAPs) of 19 acute myeloid leukemia (AML) patients an...
ORGANISM(S): Homo sapiens (Human) 
2021-03-19 | PXD018539 | Pride
Aml Lc-msms Immunopeptidome Mhc class i 
ProteomicsLC-MSMS of primary AML class I immunopeptidome (Canonical personalized proteome)
The development of therapeutic anticancer vaccines calls for the identification of tumor-specific antigens (TSAs). Though a combination of four cutting-edge proteogenomic approaches, we performed a deep exploration of the MHC-I presented peptides (MAPs) of 19 acute myeloid leukemia (AML) patients an...
ORGANISM(S): Homo sapiens (Human) 
2021-03-19 | PXD018541 | Pride
Aml Lc-msms Immunopeptidome Mhc class i 
ProteomicsLC-MSMS of primary AML class I immunopeptidome (differential k-mer expression approach)
The development of therapeutic anticancer vaccines calls for the identification of tumor-specific antigens (TSAs). Though a combination of four cutting-edge proteogenomic approaches, we performed a deep exploration of the MHC-I presented peptides (MAPs) of 19 acute myeloid leukemia (AML) patients an...
ORGANISM(S): Homo sapiens (Human) 
2021-03-19 | PXD018543 | Pride
Aml Lc-msms Immunopeptidome Mhc class i 
UnknownSARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
Not available
S-EPMC7995808 | biostudies-literature
UnknownSARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.
Not available
S-EPMC8652887 | biostudies-literature
UnknownTiming of surgery following SARS-CoV-2 infection: an international prospective cohort study.
Not available
S-EPMC8206995 | biostudies-literature
Sort   by:  
 Page size